Podcast Atlas
entity Updated 2026-08-24

Food and Drug Administration

Wake-up haul: an Ozempic moment for the brain adds a source-scoped drug-approval mention through Ovoperextone. The episode says Takeda Pharmaceutical / 武田制药’s orexin agonist was approved by the FDA to treat narcolepsy, making FDA status part of the Orexin Agonists branch while broader uses remain unproven.

Supercharging a New FDA: Marty Makary on Science, Power & Patients adds the commissioner-first reform branch through Marty Makary. The source says Makary’s FDA announced 42 reforms, changed reviewer workflows, centralized some duplicated services, expanded scientific hiring, moved toward public rejection letters and priority vouchers, and argued for FDA Review Modernization built around Clinical Trial Continuity, Post-Market Drug Surveillance, Animal Testing Substitution, and a Plausible Mechanism Pathway for some cell and gene therapies.

Bobbie: Laura Modi. How a Baby Formula Startup Took Market Share From Two Industry Giants adds the FDA’s infant formula branch through Bobbie. The source says Bobbie’s German-made pilot was recalled because the agency viewed the “companion formula” as infant formula, then later gave Bobbie the green-light letter needed for its January 2021 launch. This makes the FDA part of Infant Formula Regulatory Moat, where compliance, manufacturing, suppliers, labeling, and claims have to be solved together.

Reese’s heir vs. chocolate skimpflation adds an ordinary candy-label version of FDA relevance. The episode uses milk-chocolate and peanut-butter standards to show why Chocolate Label Standards are not just marketing words: a product labeled chocolate compound, chocolate candy, or peanut butter cream may sit outside the legal terms consumers associate with classic Reese’s.

John Coogan on Soylent, Lucy, Founders Fund, and TBPN adds the FDA through Lucy, John Coogan’s nicotine-gum company. Coogan says the regulatory pathway made the product slower and more controlled than Soylent, but also potentially created a Regulated Consumer Product Moat because competitors had to clear the same burden.

The Food and Drug Administration appears in Why is there a supplement craze if they don’t even work? as the U.S. regulator whose authority over supplements is much weaker than its authority over drugs. The source contrasts drug approval, which requires rigorous evidence, with Dietary Supplement Regulation, where many products can reach the market without proving effectiveness or ordinary premarket safety.

E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 adds a drug-regulation context through CAR-T. 刘诚 says the U.S. ultimately treated CAR-T as a drug rather than only as a medical technology, which made it subject to drug-style FDA review and safety labeling. The source also uses FDA approval thresholds and early CD19 CAR-T black-box-warning context to show why efficacy, manufacturing, and immune toxicity have to be evaluated together.

The ‘biohacking’ trend that has tech workers experimenting on themselves adds a gray-market peptide version. Jasmine Sun says users may buy injectable compounds as research chemicals from suppliers not held to FDA-approved manufacturing standards, even when the substances are personally injected and labeled “not for human use.” The source makes FDA approval a practical boundary around evidence, contents, manufacturing, labeling, and clinical oversight rather than a mere bureaucratic delay.

130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 adds the FDA as an innovation-drug ecosystem actor. The episode uses FDA approvals and oncology First-in-Class data to explain why regulators shape clinical development, evidence standards, and the division of labor between small discovery teams and large pharma launch organizations.

A trip to the magic mushroom megachurch adds the FDA as a possible future clinical-trial pathway rather than the main current regulator. John Rapp hopes psilocybin will move through FDA clinical trials, which contrasts with the source’s central religious-exemption route through the Drug Enforcement Administration and Controlled Substances Act.

The episode also uses the FDA in the Prevagen story. According to the source, the agency questioned whether the jellyfish-protein ingredient met the relevant safety threshold and later questioned NeuroShake, but the company still used GRAS Self-Certification to move through the food-to-supplement pathway described by Melanie Benish.

The sneaky way companies get new chemicals into our food adds the direct food-additive version of the problem. The source says Tara Flour entered food through Secret GRAS, so the FDA did not know the ingredient was in use until consumers became sick; the agency later banned tara flour, but the episode says it did not publicly declare that the ingredient caused the reported gallbladder and liver injuries.

Big Lettuce meets Small Intestine adds the fresh-produce and farm-safety branch. The episode says the Food Safety Modernization Act gave the FDA authority to inspect farms and enforce rules on hygiene, water, compost, manure, and animal feces in fields, but Farm Safety Inspection Capacity, Imported Produce Verification, and Foodborne Pathogen Uncertainty still limit prevention.

Tyler Shultz, Theranos Whistleblower (Part 2) adds the diagnostic-lab version through Theranos. Tyler Shultz says the FDA and CMS inspected Theranos after the Wall Street Journal reporting, and that regulatory scrutiny validated concerns about quality controls, patient samples, and lab practices that had not been addressed internally.

Surbhi Sarna, Founder of nVision Medical adds the positive medical-device version through nVision Medical. Surbhi Sarna says the company received FDA clearances in 2015 and 2016 after prototype, bench, animal-tissue, and clinical-study work, making the FDA pathway part of Medical Device Clinical Validation rather than only a post-harm or enforcement story.

Connections